Yang及其同事此前报道了一种临床引导培养方法，通过改造人类造血干细胞和祖细胞来产生异体CAR-NKT细胞。作为潜在的应用，本文作者描述了异体cd33靶向CAR-NKT细胞的设计和特性，在骨髓常驻髓系恶性肿瘤的临床前模型中显示出抗肿瘤活性。 新型免疫细胞疗法 ...

It also enables BrightPath to make use of Cellistic’s development and manufacturing capabilities, potentially accelerating the development of its BCMA CAR-NKT product. Both companies have ...